Clinical trials: Myeloid
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This randomized phase II trial is studying two different schedules of alvocidib to compare how well they work when given together with cytarabine and mitoxantrone in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00795002
- Testing
- alvocidib, mitoxantrone hydrochloride, cytarabine
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML), Adult Acute Myeloblastic Leukemia
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
This study has a phase 1 and a phase 2 component. In phase 1, the objective is to determine the maximum tolerated dose (MTD) of lenalidomide when after azacitidine.
- Trial name
- NCT00890929
- Testing
- Lenalidomide, Azacitidine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Leukemia, Myelodysplastic Syndrome
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way.
- Conditions
- Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma
- Trial name
- NCT00626626
- Testing
- Clofar, Cyclophos, Alemtuzumab, Clofar, Cyclophos,Alemtuzumab(Ph II)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Milton S. Hershey Medical Center
Acute Myelogenous Leukemia
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
- Trial name
- NCT01289678
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Leo W. Jenkins Cancer Center
Leukemia, Myeloid, Acute
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved…
- Trial name
- QUAZAR AML-001 (NCT01757535)
- Testing
- Oral Azacitidine
- Where
- 223 sites in United States, Australia and 21 more
- Volunteers
- 472 people
- Sponsor
- Celgene
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes.
- Conditions
- Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
- Trial name
- NCT00369317
- Testing
- asparaginase, daunorubicin hydrochloride, cytarabine
- Where
- 97 sites in United States, Australia and 2 more
- Volunteers
- 205 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
The goal of this clinical research study is to learn if ponatinib can help to control Chronic Myeloid Leukemia (CML) in accelerated phase. The safety of this drug will also be studied.
- Trial name
- NCT01570868
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
The purpose of this study is to compare the effects, good and/or bad, of posaconazole and micafungin in preventing fungal infections after chemotherapy for acute leukemia or myelodysplastic syndrome.
- Trial name
- NCT01200355
- Testing
- micafungin, posaconazole
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
In-Vivo Activated T-Cell Depletion to Prevent GVHD
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00594308
- Testing
- Cyclophosphamide, Fludarabine, Cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
The study of whether an infusion of blood cells called lymphocytes from a donor can stimulate the immune system to fight your leukemia/lymphoma.
- Conditions
- Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas
- Trial name
- 273 (NCT01685606)
- Testing
- cellular immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Brown University
Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
This phase II trial studies how well fludarabine and busulfan followed by a donor (allogeneic) stem cell transplant work in treating older patients with acute myeloid leukemia that is in first complete remission.
- Trial name
- NCT00070135
- Testing
- filgrastim, Anti-Thymocyte Globulin, busulfan
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Primary Objective: To estimate the probability of molecular complete remission at one year for the described sequential treatment approach, with nonablative hematopoietic transplantation, post transplant imatinib mesylate and…
- Trial name
- NCT00499889
- Testing
- Imatinib Mesylate, Fludarabine (Fludara), Busulfan
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Myeloid Hematological Malignancies
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
In this study, the investigators will use busulfan and cyclophosphamide (BuCy) backbone with the addition of fludarabine as the preparative Stem Cell Transplant (SCT) regimen.
- Trial name
- UCAML (NCT01247701)
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndromes
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
CPKC412A2104 core had a 2 stage design. In stage 1, eight participants were treated. If at least one participant showed a clinical response, four more participants were recruited to stage 2.
- Trial name
- NCT00045942
- Testing
- Itraconazole, PKC412
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Malignancies, Acute Myelogenous Leukemia
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation.
- Conditions
- Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders
- Trial name
- FLUBUTBI (NCT01366612)
- Testing
- Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Hackensack Meridian Health
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI)…
- Trial name
- NCT03082677
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Acute Myelogenous Leukemia
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs.
- Trial name
- NCT00939653
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.